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ABSTRACT  An  increasing  number  of nonviral  materials  of microbial  origin
has been reported  to stimulate the  production of interferon  in cell cultures  and
(or)  in  animals.  These  materials  include  (a)  gram-negative  bacteria  or  the
endotoxins  prepared  from  their  cell  walls,  (b)  other  microorganisms  such  as
Rickettsiae,  Bedsoniae,  Protozoa,  and  (c) fungal  products  such  as a  mannan
from  Candida and  various  antibiotics  which act  as  protein  synthesis  inhibitors,
e.g.,  glutarimide  antibiotics  and  tenuazonic  acid.  A summary  is presented  of
the current state  of knowledge  about  interferon  production  in  animals  by  the
most  thoroughly  studied  nonviral  substance  of  microbial  origin,  bacterial
endotoxin.  Further evidence  is presented which clearly distinguishes the "endo-
toxin-type"  of interferon  response  in  animals  from  the  response  seen  after  the
injection  of virus.  The  data  suggest  that  the  release  of preformed  interferon
from the  tissues occurs in animals  injected with endotoxin.  On the other hand,
interferon  produced  in  response  to the  injection  of virus  is  newly  synthesized
protein.  While  the  exact  chemical  structure  of  the  component  of  bacterial
endotoxin  responsible  for  interferon  release  has  not yet been  elucidated,  it  is
clear that the lipid portion of the lipopolysaccharide, rather than the O-specific
polysaccharide  side  chains  or  the  core polysaccharide,  is the  active moiety.
Since  the discovery  of interferon  by Isaacs  and  Lindenmann  in  1957,  it has
become apparent that the production  of this inhibitor is not solely a response
of host cells to infection by viruses. It  has been well documented that interferon
is produced  by animals  or cell cultures  exposed  to a wide variety of nonviral
stimuli.  These include  (a)  stimuli  of  microbial  origin,  (b)  substances  from
higher plants,  and  (c)  synthetic polymers.  I  have been  asked to discuss  inter-
feron stimuli  of microbial  origin.  Other contributors  to this  symposium  will
consider stimuli not covered  in this presentation.
Table  I lists the known nonviral materials of microbial  origin which have
been reported to be capable of stimulating the production of interferon  in cell
cultures  and(or)  in  animals.  For  the purposes  of  this  table,  the  term "cell
cultures"  excludes  leukocytes  obtained from  the blood  or peritoneal  cavity.
This  exclusion  precludes  the listing  as  cell  cultures  any  cells  used  directly
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TABLE  I
INTERFERON  PRODUCTION  BY  NONVIRAL
STIMULI  OF MICROBIAL  ORIGIN
Interferon production in
Stimulus  Cell cultures  Animals  References
Gram-negative  bacteria
Brucella  0*  +*  1, 2
Escherichia  0  +  3
Aerobacter  0  + 
Serratia  0  +  2
Salmonella  0  +  2
Vibrio  n.d.  +  +
Bordetella  0  +  4
Francisella  n.d.  +  5
Endotoxin  and cell wall fractions  from
Escherichia  0  +  2, 3
Aerobacter  0  + -
Salmonella  0  +  2
Brucella  0  +  6
Pseudomonas  n.d.  +  I
Hemophilus  ?  +  35
Organism other  than bacteria
Rickettsia  +  +  7, 8
Bedsonia  +  +  9
Protozoa
Plasmodium  n.d.  +  10
Toxoplasma  0  +  11,  12
Fungal  products
Candida: mannan  0  +  13
Streptomyces  (glutarimide  antibiotics)
Cycloheximide  0  +  14
Acetoxycycloheximide  0  +  15
Streptovitacin  A  0  +  15
Streptimidone  0  +  15
(Aminoglycosides)  kanamycin  n.d.  +  34
Alternaria: tenuazonic  acid  0  +  15
* 0  =  no  interferon production.
+  =  interferon  production.
n.d.  =  not  done.
TJ. S.  Youngner,  unpublished  data.
from the animal without intervening mitosis and cell division.  In  other words,
experiments  involving  the  use  of macrophages  or  other  leukocytes  are  con-
sidered  ambiguous  since these cells  are only "maintained"  in vitro.
From the  information  in Table  I  it is  readily seen  that extremely diverse
organisms  and products  are  capable  of stimulating  the production  of inter-
feron  in cell cultures  and(or)  in animals.  In  the case  of bacteria,  only gram-
negative genera have been found to be active. In my laboratory, many species
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of gram-positive  organisms  have  been  injected  intravenously  into  mice  in
concentrations  similar to those  used with gram-negative  bacteria.  In no case
have we noted  (a) the  appearance  of circulating  interferon  or  (b) the estab-
lishment of a hyporeactive  state which reduced  the ability of the animals  to
give an interferon  response  within  24-48 hr to an injection  of gram-negative
bacteria or virus  (16).  Among the gram-positive organisms  injected were  one
or more species of the following genera:  Bacillus, Mycobacterium, Corynebacterium,
Staphylococcus,  Streptococcus,  Cryptococcus,  Saccharamyces,  Candida, Hansenula.  It
should  be noted  that there has been  one report  (5)  of interferon  production
in chickens injected intravenously  with large  numbers  of living  Listeria mono-
cytogenes; heat-killed  bacteria failed  to produce  this result.
The majority  of stimuli listed  in Table I  are  active in animals  and not in
cell  cultures,  and it  is  interesting  to  consider  possible  explanations  for  this
finding.  One must suppose either the failure of cell cultures to take up effective
amounts of the stimulus  (e.g.  bacterial endotoxin)  or the large variety of cell
types  available in  the intact  animal.  This  discrepancy  in interferon  produc-
tion in cell cultures  and in  animals  has also  been  observed  in a special  case
involving  Newcastle  disease  virus  (NDV)  (17).  This  virus  is  an  excellent
stimulus of interferon production  in a continuous line of mouse fibroblasts  (L
cells).  When the virus is inactivated  by heating at 56C, its ability to induce
interferon  production  in L cells is lost.  In contrast,  the intravenous  injection
of the same heat-inactivated  NDV into mice is followed by the appearance  of
circulating interferon. This observation emphasizes that, although cell cultures
fail  to  respond,  there  are  cells  in  the  animal  which  can  interact  with  such
noninfective,  heat-inactivated  virus and produce interferon.
It is of interest to note that of the stimuli of microbial origin listed in Table
I,  Rickettsiae  and  Bedsoniae  are  the only agents  which  have  been :reported
to produce interferon  in cell cultures as well as in animals.  In contrast to all
the other agents tested,  these organisms  multiple intracellularly,  and it. is  un-
der such conditions of replication that interferon  is produced in cell cultures.
In  order  to  bring  some  order out  of the  diversity  of the  organisms  and
products  capable  of  producing  interferon  in  animals,  the  remainder  of
this presentation  will be devoted to summarizing what is known about inter-
feron production in animals by the most thoroughly studied nonviral stimulus
of microbial  origin,  acterial endotoxin.
COMPARISON  OF  INTERFERON  PRODUCTION  IN  ANI-
MALS  BY  ENDOTOXIN  AND  BY  VIRUS
1
Previous  reports  from  this laboratory  have  identified  two separate  and  dis-
tinct patterns of interferon  production  in animals: the "endotoxin  type" and
' The  methods employed  in these studies  can be briefly  summarized.  Interferon  was produced  by
the intravenous  injection of 0.1-ml volumes  of the different stimuli  into mice,  using at least  10  ani-
mals  per  sample.  At  appropriate  times,  blood  was  obtained  by  cardiac  puncture  using  heparin-
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the "virus  type"  (6,  14).  In  mice,  doses  of cycloheximide  which  effectively
inhibited  protein  synthesis  did  not  prevent  the  appearance  of  circulating
interferon  when  Escherichia coli  endotoxin  was  injected  intravenously.  This
observation  suggested  the existence  of preformed  or  precursor  interferon  in
the tissues  of intact  animals  and the  release  of this interferon  by endotoxin.
In  contrast,  the  appearance  of  interferon  in  plasma  after  the  injection  of
Newcastle  disease virus was markedly suppressed  in animals  pretreated  with
cycloheximide.  This  indicated  that  the  interferon  produced  in  response  to
injection  of  virus  was  newly  synthesized  protein.  Similar  conclusions  have
been  reached  by  Ke  and  his  coworkers  (18),  using  inhibitors  of  protein
synthesis  in rabbits.
The contrasting  effects  of blockade  of protein  synthesis  on interferon  pro-
duction  in mice inoculated  with NDV  or endotoxin  raised  questions  which
could be answered  experimentally.  In  the case  of the virus  type  of response,
is  the synthesis  of interferon  continuous  over a  10-12  hr period,  or does  the
synthesis take place shortly after the virus  is injected?  And does  release  occur
over a period of many hours? Alternatively,  is interferon synthesized through-
out  the  10  hr  period  of  rising  plasma  titers?  What  patterns  occur  when
blockade  of protein  synthesis  is  imposed  at different  times  after  the injection
of virus?
The following  experiment  was  carried  out in  an  attempt  to  answer  these
questions.  Mice  were  inoculated  intraperitoneally  with saline  or with cyclo-
heximide  (244 mg/kg)  1 hr before or  2,  4,  or  6 hr after a large dose  of NDV
was given intravenously.  Groups of  10 mice were  bled at different times, and
the interferon  content  of the pooled  plasmas  was determined.  It  can be  seen
from  the  curves  in  Fig.  1 that when  cycloheximide  was  given  1 hr  prior  to
NDV,  the  expected  90%  inhibition  of interferon  production  was  observed.
When  cycloheximide was given at 2,  4, or 6 hr after NDV, there was a shutoff
of further increase  of interferon  in the plasma.  In  fact, a marked decrease  in
titer was seen when  the  animals were bled  2 or 4 hr after cycloheximide had
been  injected.  The similar  slopes of the declining titers  after the injection  of
cycloheximide  can be interpreted  as representing  the clearance  of circulating
interferon  from the bloodstream  after  inhibition  of protein  synthesis  rapidly
curtailed further production.  These data indicate  that when NDV is used  as
the stimulus, interferon synthesis occurs throughout the period of rising plasma
concentration  and  rules  out  the  possibility  that  the  rising  titer  of plasma
interferon  is due to an early  synthesis and a slow release.
rinsed  syringes,  and  pooled  plasmas  were  tested  for  interferon  by  the  plaque  reduction  method.
Cultures  of a  continuous  line  of mouse  fibroblasts  (L  cells,  clone  929)  were  exposed  for  20  hr  to
dilutions  of plasma  and then challenged  with  40-60 plaque-forming  units  (p.f.u.)  of vesicular  sto-
matitis  virus.  The  inhibitory  titers  of the  plasma  were  expressed  as  the reciprocal  of the  dilution
which reduced  the plaque count  to  50%  of that of control  cultures.  The  details  of these  methods
have been  published  elsewhere  (17).
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HOURS  AFTER  INOCULATION  OF  NVD
FIGURE  1.  Influence  of time of injection  of cycloheximide  on interferon  production  in
mice  by NDV.  Mice  (31  g)  were  inoculated  i.p.  with  1.0  ml of  saline or with  cyclo-
heximide  (244 mg/kg)  at different times before or after NDV (2  X  108 p.f.u.)  was given
i.v.  (O  hr). Interferon  titers for animals injected with: saline at -1  hr (o); cycloheximide
at  -1  hr  (),  at +2 hr (- *A-), at  +4  hr (- -A-  -),  or at  +6  hr (-A-). Cyclohexi-
mide alone  produced  an interferon  titer  of 320  at 10  hr  (from reference  15).
The pattern  of interferon  release  in mice given  endotoxin  was studied  by
the same technique.  Mice were  inoculated  with saline  or with cycloheximide
at  different  times  before  or  after  100  g  of  endotoxin  was  injected  intra-
venously.  The  interferon  titer  of pooled  plasma  was determined  at different
times after the injection of endotoxin,  and the results  are plotted in Fig.  2. As
expected,  endotoxin  produced the usual early peak titer of plasma interferon
in control  animals pretreated  with saline.  Cycloheximide  injected  1 hr prior
to endotoxin produced an enhanced and prolonged interferon response.  When
the  injection  of cycloheximide  was  delayed  until  2  hr after  endotoxin  was
given  (when plasma  interferon titer  had  reached  its  peak),  no  enhancement
or prolongation of the interferon  response was elicited.  These results indicated
that  the  events  involved  in  the potentiation  of interferon  release  by  cyclo-
heximide  occurred  earlier  than 2 hr after the injection of endotoxin.
In  order  to  determine  more  precisely  the  early  events  involved  in  the
potentiation of interferon release by cycloheximide in animals given entotoxin,
the following experiment was carried out.  Mice were given cycloheximide  60
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HOURS  AFTER  INOCULATION  OF  ENDOTOXIN
FIGURE  2.  Influence  of time  of  injection  of cycloheximide  on  interferon  production
in mice  by  endotoxin.  Mice  (30  g) were  inoculated  i.p.  with  1.0  ml of saline  or with
cycloheximide  (244  mg/kg)  at different  times before  or  after  endotoxin  (100  /ug)  was
given i.v.  (0 hr). Interferon  titers for  animals injected  with:  saline at  -1  hr (o); cyclo-
heximide  at  -I  hr (),  at  +2 hr  (.  A.  ), at  +4  hr (--A--), or  at  +6 hr (-A-).
Cycloheximide  alone produced  an  interferon titer of 250  at 10  hr  (from  reference  15).
min before,  or at the same  time,  that endotoxin  was  injected  intravenously
other  animals were injected with cycloheximide  15,  30,  60,  or  120 min after
the endotoxin was given. Groups of animals were bled at appropriate intervals,
and  the  interferon  titers  of the  plasma  pools  were  compared  to  the  titers
obtained in animals given saline  60 min prior to endotoxin,  or in those given
only cycloheximide. The data in Table II  show that cycloheximide produced
an enhanced  and prolonged  interferon  release  when given  to mice up  to 30
min after  the endotoxin  was injected.  By 1 or 2 hr after the injection of endo-
toxin,  no significant enhancement  of interferon  release  was produced  by the
blockade  of protein  synthesis.  These results  indicate  that the critical  events
involved in the release of interferon  by endotoxin  occur  within  30 min  after
the stimulus is injected.
It  is  necessary  at this point  to make an  exception  to the limits  set on the
scope  of this presentation;  essential  data  dealing  with interferon  production
in mice by a synthetic polymer are included for reasons that will be apparent.
We have reported previously that there is  a striking  similarity between  inter-
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TABLE  II
TIME  OF  INJECTION  OF  CYCLOHEXIMIDE:  INFLUENCE
ON  INTERFERON  PRODUCTION  IN  MICE  BY  ENDOTOXIN*
Interferon titer of plasma at
Mice  inoculated  with  At 0 time (i.v.)  2 hr  5 hr  8 hr
min
Salines at:  -60  50 pg  endotoxin  400  65  40
Cycloheximide§  at:  -60  50  ug  endotoxin  280  5,200  7,600
0  "  120  2,600  7,500
+15  200  1,700  4,000
+30  "  700  2,000  4,700
+60  "  900  500  n.d.11
+120  450  520
Cycloheximide only  at:  -60  - <32  110  200
*From  reference  15.
1.0  ml  intraperitoneally.
§ 244  mg/kg  in  1.0  ml  saline  intraperitoneally.
II  Not done.
feron  production  in mice  by poly rI:rC,  a  synthetic  double-stranded  poly-
ribonucleotide,  and  by endotoxin  (19).  As in  the  case  of mice  injected  with
endotoxin,  suppression  of protein  synthesis  by  cycloheximide  produces  an
enhanced  and  prolonged  interferon  response  to  poly r:rC. An  experiment
similar  to  the  one  described  above  for  endotoxin  was  performed  with  poly
rI:rC  to  determine  the temporal  relationship  between  blockade  of protein
synthesis  and  enhancement  of interferon  release  in  mice.  Mice  were  given
cycloheximide  at different times before and  after the intravenous  injection  of
10  jug  of poly rI :rC. Groups  of animals were  bled  at appropriate  intervals,
and  the interferon  titers  in plasma  were  compared  to  the  titers  obtained  in
animals  given  saline  60 min prior  to  poly rI:rC.  It was  found  (Table  III)
that cycloheximide enhanced interferon  release when the  antibiotic was given
up  to  2  hr  after  the  poly  rI:rC.  Maximum  enhancement  was  produced
when  the antibiotic  was injected  before,  or  1 hr after,  the  poly rI :rC. These
results confirm  the similarity of interferon  production  in mice by  a synthetic
double-stranded  polynucleotide  and  by  endotoxin  and  emphasize  the  im-
portance  of early interactions  between  host cells and  the stimuli which cause
a  release  of  preformed  interferon  into  the circulation.  Similarities  between
endotoxin  and  poly  rI:rC with regard  to  their  effects  in  animals  have  also
been confirmed  in other experiments  (20,  21).
The experiments which have been described provide additional information
about the two different patterns of interferon production in mice injected  with
virus or bacterial  endotoxin.  Blockade  of protein  synthesis  at  different  times
31 INTERFERON  INDUCTION.  I
TABLE  III
TIME  OF  INJECTION  OF  CYCLOHEXIMIDE:  INFLUENCE
ON  INTERFERON  PRODUCTION  IN MICE  BY  POLY  I:C*
Interferon titer of plasma at
Mice inoculated  with  At 0 hr  (i.v.)  2 hr  5 hr  8  hr
hr
Salinet at:  -1  10  g poly I:C  250  200  100
Cycloheximide§  at:  -1  10  /Ag  poly I:C  100  4,200  10,000
+1  "  300  2,500  6,000
+2  "  410  1,000
+3  "  170  320
+5  < 128
Cycloheximide only  at:  - - 60  200
* From reference  15.
t1.0 ml intraperitoneally.
§ 244 mg/kg in  1.0 ml saline  intraperitoneally.
after injection  of NDV  established  that the  interferon  synthesis  induced  by
virus is continuous for at least  10-12 hr. This finding ruled out the possibility
of early synthesis  and later  release  following induction of interferon  synthesis
by the virus.  In  addition,  these  results  seem  to refute  the  hypothesis that in
the  virus-induced  interferon  response  protein  synthesis  was  needed  for  the
synthesis  of  an  enzyme  (or  enzymes)  capable  of  activating  a  preformed
precursor interferon molecule (6). The sharp decrease of circulating interferon
which  resulted  from  blockade  of  protein  synthesis  at  different  times  after
injection  of  NDV  did  not  support  a  mechanism  involving  a  hypothetical
interferon-activating  enzyme.  One would  expect  an  enzyme  with  a  reason-
ably long half-life to function for  a significant period  of time.
The mechanism  by which the inhibition of protein  synthesis  in the animal
enhances  and  prolongs  the  interferon  response  elicited  by  endotxin  is  not
clear.  The importance of very early events in the interaction  of endotoxin and
host  cells  is  shown  by the need to give  the protein  synthesis inhibitor within
30 min after the endotoxin is  injected.  Since endotoxin produces  a 2 hr peak
of  circulating  interferon  under  ordinary  circumstances,  it  is  apparent  that
the  release  of  interferon  from  the  participating  host cells  is  effected  rather
quickly.  Significant  amounts  of  interferon  appeared  in  the  circulation  be-
tween  30 and  60 min  after  the  intravenous  injection  of endotoxin  (2).  It  is
possible  that the  enhancement of interferon  production by endotoxin in  ani-
mals pretreated with protein synthesis inhibitors may be the result of a failure
of  detoxifying  mechanisms  dependent  on  protein  synthesis.  The  failure  of
early detoxification  of endotoxin could  permit the involvement  of more  cells
in the release of interferon over a longer period of time.  In addition,  the release
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of  interferon  by  glutarimide  antibiotics  or  tenuazonic  acid  alone  is  a  phe-
nomenon  which must  be taken  into  consideration.  The  enhancing  effect  of
the antibiotics on interferon release by endotoxin may be the result of a syner-
gistic  action of the  two agents  by mechanisms  which  are poorly  understood
and  difficult to determine  in intact  animals.  It  is of interest that Vilcek  and
his  coworkers  (22;  J.  Vil6ek,  personal  communication)  have  reported  that
inhibition  of protein  synthesis  enhances  and  prolongs  interferon  production
in rabbit  kidney  cells  stimulated  by  poly rI:rC.  The  interferon  production
curves  they described  were strikingly similar to those we have  found in mice
given poly rI: rC or endotoxin. The availability of a cell culture  system for the
study of the phenomena involved in release  of preformed precursor  interferon
may make  feasible  experiments which cannot be done in animals.
INVESTIGATIONS  OF  THE  CHEMICAL  PORTION  OF  BAC-
TERIAL  ENDOTOXIN  RESPONSIBLE  FOR  RELEASE  OF
INTERFERON  IN  ANIMALS
Earlier  presentations  in  this  symposium  have  dealt  with  the  mechanism  of
induction of interferon  synthesis in cells infected  with viruses.  In  this section
of my  presentation,  I  shall  summarize  our  attempts  to  determine  which
chemical  structure  of complex  endotoxin  preparations  is  responsible  for the
release  of  interferon  in  mice  (23-25).  These  experiments  were  carried  out
with  Salmonella  typhimurium mutants  with  known  mutational  blocks  in  the
biosynthesis  of cell  wall lipopolysaccharides  (26-29).
Using  intravenous  injection  of suspensions  of intact  heat-killed  Salmonella
typhimurium mutants, it was found that the interferon  response elicited in mice
was not dependent on the presence of a complete cell wall lipopolysaccharide.
In fact, a mutant (G30/C21) which has lost all the polysaccharide  side chains
and  sugars  of the O-antigen  and  contains  only  2-keto-3-deoxyoctonate  and
lipid  was indistinguishable  in its  interferon-stimulating  ability from the  wild
type  (LT-2)  which possesses  a complete  O-antigen  with polysaccharide  side
chains.  This conclusion,  based on the  use of intact  heat-killed  bacteria, was
confirmed  using lipopolysaccharides  and  glycolipids  extracted  from  the  dif-
fernt mutants by methods which have been described elsewhere  in detail (24).
The data obtained  with these materials showed that purified cell  wall glyco-
lipid from the  heptoseless mutant G30/C21  and lipopolysaccharide  from the
wild-type  organism  did  not  differ  significantly  in  their  interferon-releasing
activity in mice. These results suggested that it was not the polysaccharide  or
heptose-phosphate  backbone portion  of endotoxin  which was responsible  for
the release of interferon.  Itwas essential, however, to eliminate two possibilities:
(a) that despite mutational blocks in synthesis of complete O-antigen,  certain
polysaccharide  components  could  be  present  but  not  incorporated  into  the
cell  wall  of the  deficient  mutants  and  (b)  that  these  components  were  re-
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sponsible  for  the  interferon-stimulating  effect  of  whole  cells  with  major
deficiencies  in cell wall  composition.
Interferon-releasing  activity of O-specific  hapten and  core glycolipid  were
studied  in  the  following  manner.  Core  glycolipid  from  strain  TV-161  (Rb
chemotype)  was prepared  by a phenol extraction  technique  which has been
described  elsewhere  (24).  Pure  O-specific  hapten  from  strain  TV-161  was
isolated  by the method  of Kent and  Osborne  (30).  Both the  core glycolipid
and O-specific hapten of strain TV- 161  were tested in mice for their interferon-
releasing  activity.  Pretreatment  of  mice  with  244  mg/kg  of cycloheximide
was used to enhance interferon release (14).  In addition to interferon-releasing
activity,  the  lethality of the  bacterial preparations  was  tested.  Groups  of  10
mice were injected intravenously with twofold dilutions of the materials under
test, and deaths were recorded over a  72 hr period.  The  LD50  was calculated
by the  method  of Reed  and Muench  (31).  The lethal effect  of the prepara-
tions  tested  was potentiated  by pretreatment  of the  mice with  80  mg/kg of
cycloheximide,  a dose  of antibiotic  which causes  a transient  interruption  of
protein  synthesis  but is  not in  itself lethal  (14,  15).  From the data in Table
IV  it can  be  seen  that core  glycolipid  was lethal  only  for  mice pretreated
with cycloheximide,  the LD50  being about 40  /Ag  in these animals.  In contrast,
10-fold  greater  doses  of the  pure  hapten had  no  demonstrable  lethality  for
mice.  With  regard  to  interferon,  the  dose  response  to  core  glycolipid  was
similar  to  what  would  be  seen  following  injection  of complete  lipopolysac-
charide  with O  side-chains  or with  Re chemotype  glycolipid.  However,  no
evidence  of  interferon  release  by  hapten  was  observed;  even  in  mice  pre-
treated with 244 mg/kg  of cycloheximide,  a  dose which markedly enhanced
interferon  release  by core  glycolipid,  the  level  of interferon  present  in mice
treated with hapten  did  not differ  significantly  from that released  by cyclo-
TABLE  IV
EFFECT  IN  MICE  OF  S.  TYPHIMURIUM  (TV-161)
GLYCOLIPID  AND  HAPTEN  FRACTIONS*
Issa  dose in mice  treated  with  Interferon titer of plasma of mice treated  with
Cycloheximide  Cycloheximide§
Preparation  Saline  (80 mg/kg)  Dose  SalineS  (244  mg/kg)
pg  Ag  Pg
Core glycolipid  >500  39  100  180  7200
10  210  4000
Hapten  >500  >500  100  <32  400
10  <32  100
Saline  - - - <32  340
* From reference  25.
Mice bled  at 2 hr.
§ Mice bled at  8 hr.
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heximide  alone.  Detailed  analytical  data obtained  spectrometrically  and  by
gas-liquid  chromatography  (32)  showed  that  the contamination  of hapten
by core glycolipid was negligible.
The essential role of the lipid portion of Salmonella lipopolysaccharide  in the
production  of interferon  in mice was demonstrated  in the following manner.
Glycolipid  from  the  heptoseless mutant  G30/C21  (Re chemotype)  was  hy-
drolyzed  by  acid  treatment  to  produce  a  series  of  hydrolysates  containing
decreasing  amounts  of  KDO  (2-keto-3-deoxyoctonate)  (33).  The  macro-
molecular  materials  produced  by partial  hydrolysis  were  isolated  by ultra-
centrifugation, washed with water, and lyophilized. The conditions of hydroly-
sis and the interferon-releasing activity of a number of materials are presented
in  Table  V. It can  be  seen  that  acid  treatment  of G30/C21  glycolipid  hy-
TABLE  V
INTERFERON  PRODUCTION  IN  MICE  BY  S.  TYPHIMURIUM  LIPOPOLY-
SACCHARIDE  AND  GLYCOLIPIDS-EFFECT  OF  ACID  TREATMENT*
Interferon titer of plasma of mice
treated with
Glycolipid  or  Residual
lipopolysaccharide  KDO  Cycloheximidell
(chemotype)  Treatment  content  Dose  Saline§  (244 mg/kg)
%  Ag
G30/C21  (Re)  None  100  100  370  3000
10  160  2100
1  100  700
0.05 N Acetic  acid  (pH 3.1)  58  100  300  2600
5 min 100
0C  10  250  1500
1  300  450
0.05  N Acetic  acid  (pH 3.1)  44  100  250  2000
10  min 100
0C  10  220  1200
1  80  280
0.05  N  Acetic acid  (pH 3.1)  20  100  260  2000
20 min 100
0C  10  260  1200
1  <32  500
0.02  N H2SO4 (pH  1.7)  0  100  360  2800
20 min 100°
0C  10  320  850
1  45  700
LT-2  (S)  None  100  100  270  2000
10  290  1300
1  180  700
Saline  only  - - <32  70
* From reference  25.
The KDO  content of native G30/C21  glycolipid  (18%)  was  taken as  100%.
§Mice  bled at 2  hr.
I] Mice bled  at 8 hr.
¶ These  conditions of hydrolysis  yield Lipid A  (25).
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drolytically removes KDO from the compound;  however,  this hydrolysis  does
not alter the interferon-releasing  activity of the material.  In fact,  hydrolyzed
glycolipid  from  strain  G30/C21,  from which  all  detectable  KDO  had been
removed,  was identical with LPS (lipopolysaccharide)  from the wild-type or
ganism  in  interferon-releasing  activity.  Similar  results  have  been  obtained
with glycolipids  from two different Salmonella species  (25).
The  results  which  have  been  presented  show  that  wild-type  Salmonella
typhimurium lipopolysacchardide  and glycolipids from Rb and Re chemotypes
are  equally  active  in  releasing  interferon  in  mice.  Furthermore,  materials
obtained by graded acid hydrolysis of Re glycolipid,  resulting in lipid products
with decreasing  content  of KDO,  did  not  differ  from lipopolysaccharide  in
their  interferon-releasing  activity.  Lipid  A,  which  contains  no  KDO,  was
also fully active in releasing interferon. While the exact nature of the chemical
structure  responsible  for  interferon  release  has not yet been  elucidated,  it is
clear  that the  lipid  portion  of the lipopolysaccharide,  rather  than the poly-
saccharide  side chains  or the core polysaccharide,  is the  active moiety.
The  studies  on  bacterial  lipopolysaccharide  were  planned  and  executed  in  collaboration  with
Dr.  David  Sidney  Feingold  and  Mr. Joseph  Chen.
This  investigation  was  conducted  under the  sponsorship  of the  Commission  on  Influenza,  Armed
Forces  Epidemiological  Board,  and was  supported  by the  U. S.  Army  Medical Research  and De-
velopment Command,  Department  of the Army,  under research contract  No. DADA  17-67-C7046,
and  in part by  Public Health  Service  research  grant  No.  AI-06264  from the  National  Institute  of
Allergy and  Infectious  Diseases.
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Discussion  from the Floor
Dr.  B.  L.  Wasilauskas (Columbia-Presbyterian  Medical  Center,  New  York):  I'd
like  to ask Dr. Youngner  if he  has ever used  any other acid hydrolysis  to obtain  his
KDO.  I  noticed he used 0.2 N sulfuric.  I was just wondering if he  ever used hydro-
chloric  or  formic  acid.  We've  used  these  procedures  and  found that we  were  able
to isolate KDO in significant amounts, using 1 N and higher normalities  of these acids
for periods up to 30 min.
Dr. Youngner: The only other  acid  treatment  that we've used  is,  I believe,  0.05  N
acetic  acid for longer periods  of time,  and we've obtained  graded  hydrolysis. We've
never used the  acids which you mentioned.
Dr.  Wasilauskas: What  procedures  did  you  use  to  determine  your  KDO?  The
TBA method?
Dr. Youngner: That's right, the method of Osborne.
Dr. Wasilauskas: And you were not able to isolate  KDO from sulfuric acid?
Dr. Youngner: We were  not. We  hydrolyzed  the KDO  and separated  the material
by ultracentrifugation  after  treatment. There was  no KDO present in this material.
We could account for it all in the hydrolysate.
Dr.  Wasilauskas: Also,  I'd  like to  ask  if you've  had  any problem with this  glucan
that Nikaido  has indicated is present in many lipopolysaccharide  preparations?
Dr. Youngner:  From the analytical  material,  which I did  not present  for purposes
of brevity, it is not likely that we have contamination  with this  material.
Dr. Levy:  Let  me  presume  upon  my  authority  as  the  Chairman  to  ask  a  more
generalized  question.  The  nature  of  preformed  interferon  has  been  a  troublesome
concept  for  many  people,  including  myself.  As  everybody  has  observed,  you  can
stimulate  an  animal  to release  the  preformed  material.  Then you can't stimulate it
again  immediately,  but  after  a  reasonably  short period  of  time  the  animal  can  be
restimulated.  This  implies,  I  think,  a  replenishment  of the  supplies  of the  stored
material.  Does this  mean  that interferon  is  being continually  produced  and  stored
up somehwere,  or is the preformed material present in the animal as  a result of prior
infections?  How do you envision this?
Dr. Youngner: This is  a rather  difficult question to  get at experimentally,  but what
we've assumed is that the depletion effect by the first inoculation is due to  the toxicity
of the materials.  This depletion may result from  release,  and  then the interferon  has
to  be  resynthesized.  Or there  may  be  appreciable  destruction  of the  cells  involved,
and then these cell populations would have to be repopulated  in order for the animal
to become  reactive  again.  The  interesting  thing is that there  is what  we  refer to  as
cross-hyporeactivity,  so that  an  injection  of lipopolysaccharide  produces  hyporeac-
tivity to  virus,  and vice  versa.  This  must  mean that the  same  cells  are  affected by
the  first  stimulus  in  terms  of  its  toxicity  or depletion  effect,  and  then  the  second
stimulus  cannot  act.  Two  different  mechanisms  are  envisaged  here,  release  or syn-
thesis.  It's possible that cells are capable  of more than one type of interferon response,
and we  have to take that into consideration,  too.
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From the Floor: Has  the same  experiment  been  done  with germfree  mice,  because
it could perhaps  exclude  the possibility  that previous infection produces the interferon
which is  released?
Dr. Youngner: We  have not done  any experiments  with germfree  mice,  but others
have reported that germfree  mice give good  interferon  responses with endotoxin.
Dr. Lockart: I  would  like  to  add  a comment  to your  previous  question,  Dr.  Levy,
concerning  whether  some  interferons  might  not  be  being  made  continuously  in
animals.  I have here six references that are in the literature which show that lymphoid
cells,  of various sorts,  kept in culture  can make  interferon spontaneously.
We  reject  the  idea  of  spontaneous  interferon  production  by saying  that  because
most of these cells  are from leukemia patients  they are really infected cells and there's
a latent inducer there. But I think that when you start accumulating  this much  data
that some  cells  make interferon  over  long  periods  of time  continuously,  we  may be
at the stage  where  we should consider  that not all interferon  has  to be induced.
Dr. Youngner:  I would  like  to  make  one  additional  comment.  I recall  to  you  my
stricture  in what I classified  as  cell  cultures  in  the first four  slides  I showed.  It was
because  of this  stricture  and  the  ambiguity of  the  use  of lymphoid  cells,  peritoneal
exudate  cells, and buffy-coat cells  from animals  that I did not call them cell cultures
but "maintained"  cells because  there have been so many references  to these primary
cells producing  interferon  without any stimulus added.
Dr. Levy: Just as further reference to Dr. Lockart's  comments to my question-With
Dr.  Haase  we  have  shown  similar  effects  with  lymphocytes  and  have  pretty  well
excluded  the likelihood that infecting virus is responsible for the continuous interferon
production  by lymphocytes  in culture.
Dr.  Robert M. Friedman:  You can produce interferon in rabbit cells  in the presence of
cycloheximide  and  antinomycin.  We  have  done  extensive  work  in  human  cells  in
culture and shown  the same thing. Although  we were very skeptical when we started
this work,  I think we have  come  around  to the feeling  that there  is  such  a thing as
preformed  interferon in  constant production.  In my lab  we have tried to sum this up
in a form that's easy to remember  and maybe  familiar  to all of you--"You can  take
interferon  out of the animal, but you can't take the animal out of interferon."
Dr. James G.  Gallagher (University  of Vermont,  Burlington,  Vt.): Dr.  Youngner,
would you care  to comment on  the mechanism  of release of interferon  elicited  by the
active  lipid fraction?  What do you  envisage  actually  occurs  at the molecular  level?
Is this a membrane-mediated  function?
Dr. Youngner: It took us 3 yr to get Bob Friedman  to admit that there  may be such
a thing  as  preformed  interferon,  and I'm  afraid it will take  me  twice as long to be
able  to  answer  your question.  This  is  very  difficult  for  us to  even  get  at,  although
efforts with  these purified materials are  going to be made. I have absolutely no idea.
Dr. Gallagher: Is it possible  that a physical  interaction  between  the lipid  and  the
cell  membrane  results in  a  lesion,  rendering  the  cells  in  a  sense  "leaky,"  the  end
result being a release of preformed interferon? This hypothesis appears to be consistent
with an interpretation of the enhancing effect of cycloheximide on release of preformed
interferon  as possibly being due to inhibition  of repair  of membrane  defects.
Dr. Youngner: This I  find as general as your original question.  That there is  some
damage  to the membrane which releases  interferon  still doesn't tell us  in what state
the  interferon  is  in  the  cell,  or  what  that particular  lesion  at the  membrane  is.  I
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think  these  are  very  difficult  and  thorny  questions  for which  to  design  the proper
experiments.
From the Floor: I have a question about endotoxin which has been earlier  described
as an immunologic  adjuvant.  And now  here, years  later,  we're describing endotoxin
lipid  as  an interferon inducer.  I wonder if you care  to speculate  on any  relationship
existing at  all between  endotoxin  as viral  immunologic  adjuvant,  and endotoxin  as
interferon  inducer.
Dr.  Youngner: Well,  I certainly won't make  a  single comment on  endotoxin as  an
inducer,  but I will make a comment  on  interferon  release  by endotoxin  and immu-
nologic  adjuvants.
These  effects we observe  are rather  quick. The interaction of endotoxin with  cells
showed that interferon  release  in mice occurred  within  a half hour.  I think the stim-
ulating effects on antibody  production,  under certain  conditions,  that endotoxin  has
been  shown  to have  by many  different workers,  are  effects which  go on for a period
of days  or  weeks.  I haven't got the  vaguest idea  whether  they  are  even  interacting
with the same cells.  I think it is very difficult to  sort these out.
What we're trying to do is to dissect the chemical portions of the endotoxin molecule
which  are responsible  for the adjuvant effects of the  endotoxin,  and the part of this
complex molecule  that is responsible for the  interferon  release.  And this may give us
some clues  as to how to approach the questions that you raise very accurately.
Dr. Richard H. Adamson (National Institutes  of Health, Bethesda,  Md.): You seem
to  feel  it  is  the lipid  portion  of your  molecule  that's  important.  Have  any  simple
lipids or naturally-occurring  lipids been tested to  see if they release  interferon?
Dr. Youngner: We haven't  done  any. I'm just trying to think whether anybody else
has.  But we  are  very much  involved now  in  creating  models.  Lipid A  is a  difficult
material  to work  with. We're doing the  things  that can be done with the  chemistry
of  lipid A, but we're  also  trying to  create  models  of  lipid A  structure  with  which
we'll  be able to work. There are some advantages  to lipid A, as far as one may bring
in the practical here. It  is a substance we all carry around with us and it would offer
few complications  in using such material as an interferon stimulus.  In fact,  one could
even  go wild and speculate  that the  autolysis  of intestinal  organisms  and  the release
of lipid A,  or products like  it, could be the  source of some  of the innate resistance  to
virus infection,  that is,  by  constant,  low  level  stimulation  of interferon  production;
but that's pretty wild. But we  are looking  at models.
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